Mucoactive drugs

Balsamo R., Lanata L., Egan C. G.

Source: Eur Respir Rev 2010; 19: 127-133
Journal Issue: June 2010 - 19 (116)
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Balsamo R., Lanata L., Egan C. G.. Mucoactive drugs. Eur Respir Rev 2010; 19: 127-133

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis
Source: International Congress 2019 – Treatment of airway diseases in primary care
Year: 2019

Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009

Anti-inflammatory therapies in bronchiectasis
Source: Eur Respir Mon 2011; 52: 223-238
Year: 2011


Pharmacological agents used to treat asthma
Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=339
Year: 2003

Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001

Anti-asthmatic drugs: treatment of athletes and exercise-induced bronchoconstriction
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-22-7, page=73
Year: 2005

Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017
Year: 2018



Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017
Year: 2018



Tolerance of two cox2 - inhibitors, rofecoxib and celecoxib, in aspirin sensitive asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 428s
Year: 2001

Single-dose desloratadine and montelukast and allergen-induced late airway responses
Source: Eur Respir J 2009; 33: 1302-1308
Year: 2009



The inhibitory effect of salbutamol on neutrophil's respiratory burst is enhanced by the SH-metabolite of erdosteine (mucoactive drug)
Source: Eur Respir J 2002; 20: Suppl. 38, 617s
Year: 2002

The inhibitory effect of ciprofloxacin on bacterial adhesiveness is enhanced by the SH-metabolite I of erdosteine (mucolytic drug)
Source: Eur Respir J 2001; 18: Suppl. 33, 543s
Year: 2001

Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations
Source: Eur Respir J 2007; 30: 1143-1149
Year: 2007



Anti-inflammatory effects of formoterol and fluticasone propionate in bronchial epithelial cells
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015

Mucoactive therapy in COPD
Source: Eur Respir Rev 2009; 19: 134-140
Year: 2010



Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis
Source: Eur Respir J 2002; 19: 294-302
Year: 2002



Long-term use of antioxidant mucolytic erdosteine is especially beneficial in patients with more severe COPD
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008


Emerging inhaled bronchodilators: an update
Source: Eur Respir J 2009; 34: 757
Year: 2009



RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016

Mucolytics and anti-inflammatory lung treatments
Source: ERS course 2015
Year: 2015